{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:35:16Z","timestamp":1791041716093,"version":"4.1.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:sec id=\"ab-ooi230050-4\"><jats:title>Importance<\/jats:title><jats:p>Patients undergoing radiation therapy (RT) for head and neck squamous cell carcinoma (HNSCC) experience a range of debilitating adverse effects (AEs). Patient-reported outcome (PRO) measures to quantify these AEs are a necessary and important component of health care; however, currently available PRO options often measure only disease-related symptoms or AEs of non-RT treatments.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230050-5\"><jats:title>Objective<\/jats:title><jats:p>To develop a brief PRO measure of the most common AEs associated with RT for HNSCC.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230050-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a qualitative study that followed the US Food and Drug Administration guidelines to develop a brief measure of patient-reported RT-related AEs (the Functional Assessment of Cancer Therapy\u2013Head and Neck Radiotherapy [FACT-HN-RAD] measure). The study included (1) a literature review of clinical trials; (2) secondary analysis of retrospective concept elicitation interviews (CEIs); (3) electronic surveys of practicing radiation oncologists; (4) mapping of existing items to inform the development of the draft version of the measure; and (5) validation of content and face validity via patient cognitive interviews. Analysis was performed of CEI data and interviews with practicing radiation oncologists. Data analysis was conducted from July 1, 2022, to April 21, 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230050-7\"><jats:title>Exposures<\/jats:title><jats:p>Surveys and qualitative interviews.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230050-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The most common patient-reported RT-related AEs among patients with HNSCC.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230050-9\"><jats:title>Results<\/jats:title><jats:p>Of 19 CEI participants, 14 (mean [range] age, 67 [49-86] years; 12 [86%] men and 2 [14%] women) described RT-related AEs and were included in the secondary analysis. Eleven (79%) patients reported difficulty swallowing; 8 (57%), oral pain; 7 (50%), dry mouth; 7 (50%), weight loss; 6 (43%), skin burning; 5 (36%), loss of taste; 5 (36%), voice changes (36%); and 5 (36%), fatigue. Nine radiation oncologists (mean [range] time in practice, 8 [1-42] years; 5 [56%] men and 4 [44%] women) reported the most common AEs: 9 (100%) reported dysgeusia; 7 (78%), xerostomia; 7 (78%), mucositis or oral pain; 8 (89%), dysphagia or odynophagia; 6 (67%), dermatitis; and 3 (33%), fatigue. Together these data informed the development of an 8-item AE-focused measure of pain, dysphagia, xerostomia, dysgeusia, voice changes, dermatitis, fatigue, and weight loss. Cognitive interviews with 10 patients (mean [range] age, 61 [29-84] years; 8 [80%] men and 2 [20%] women) demonstrated strong face validity; all (100%) reported that the measure reflected their experience with RT and stated that the length of the questionnaire was \u201cjust right.\u201d<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230050-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The 8-item FACT-HN-RAD measure captures the most common patient- and physician-reported AEs related to RT for HNSCC. This measure offers a means to serially monitor patient-reported treatment-related AEs and recovery over time in both clinical and research settings. Future work will evaluate the psychometric validity of the measure.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoto.2023.2177","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T15:03:07Z","timestamp":1692284587000},"page":"884","source":"Crossref","is-referenced-by-count":16,"title":["Monitoring Adverse Effects of Radiation Therapy in Patients With Head and Neck Cancer"],"prefix":"10.1001","volume":"149","author":[{"given":"Laila A.","family":"Gharzai","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Northwestern University, Chicago, Illinois"},{"name":"Department of Medical Social Sciences, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Mierzwa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Devin","family":"Peipert","sequence":"additional","affiliation":[{"name":"Department of Medical Social Sciences, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kedar","family":"Kirtane","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Casper","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Rothrock","sequence":"additional","affiliation":[{"name":"Department of Medical Social Sciences, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[{"name":"Department of Medical Social Sciences, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Shaunfield","sequence":"additional","affiliation":[{"name":"Department of Medical Social Sciences, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"18","key":"ooi230050r1","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1200\/JCO.19.00370","article-title":"Evolution of the oropharynx cancer epidemic in the United States: moderation of increasing incidence in younger individuals and shift in the burden to older individuals.","volume":"37","author":"Tota","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10166","key":"ooi230050r2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"ooi230050r3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.20.02072","article-title":"ARTSCAN III: a randomized phase iii study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer.","volume":"39","author":"Gebre-Medhin","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"ooi230050r4","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ijrobp.2019.08.038","article-title":"NRG-HN002: a randomized phase ii trial for patients with p16-positive, non-smoking-associated, locoregionally advanced oropharyngeal cancer.","volume":"105","author":"Yom","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ooi230050r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104853","article-title":"Characterization of very late dysphagia after chemoradiation for oropharyngeal squamous cell carcinoma.","volume":"111","author":"Gharzai","year":"2020","journal-title":"Oral Oncol"},{"key":"ooi230050r6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1477-7525-8-104","article-title":"Health care providers underestimate symptom intensities of cancer patients: a multicenter European study.","volume":"8","author":"Laugsand","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"ooi230050r7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.radonc.2019.04.030","article-title":"Big data analysis of associations between patient reported outcomes, observer reported toxicities, and overall quality of life in head and neck cancer patients treated with radiation therapy.","volume":"137","author":"Wilkie","year":"2019","journal-title":"Radiother Oncol"},{"issue":"5","key":"ooi230050r8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archotol.1996.01890170018005","article-title":"Quality of life and functional status measures in patients with head and neck cancer.","volume":"122","author":"D\u2019Antonio","year":"1996","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"7","key":"ooi230050r9","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients: the MD Anderson Symptom Inventory.","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"ooi230050r10","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.1999.17.3.1008","article-title":"Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.","volume":"17","author":"Bjordal","year":"1999","journal-title":"J Clin Oncol"},{"issue":"4","key":"ooi230050r13","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.401","article-title":"Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and\/or metastatic squamous cell carcinoma of the head and neck: content validation of the Functional Assessment of Cancer Therapy\/National Comprehensive Cancer Network Head and Neck Symptom Index-10 (FHNSI-10).","volume":"4","author":"Shaunfield","year":"2021","journal-title":"Health Sci Rep"},{"issue":"2","key":"ooi230050r14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology.","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"ooi230050r16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation.","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"ooi230050r17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.","volume":"321","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"ooi230050r18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2018.18085","article-title":"Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer.","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"ooi230050r19","article-title":"Using patient-reported outcomes to describe the patient experience on phase I clinical trials.","volume":"4","author":"Sedhom","year":"2020","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"16","key":"ooi230050r20","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2022.17064","article-title":"Recommendations for care of survivors of head and neck cancer.","volume":"328","author":"Auger","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"ooi230050r21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/pon.1346","article-title":"Fear of recurrence and psychological distress in head and neck cancer patients and their carers.","volume":"18","author":"Hodges","year":"2009","journal-title":"Psychooncology"},{"issue":"S5","key":"ooi230050r22","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.5694\/j.1326-5377.2010.tb03928.x","article-title":"Psychological distress (depression and anxiety) in people with head and neck cancers.","volume":"193","author":"Neilson","year":"2010","journal-title":"Med J Aust"},{"issue":"22","key":"ooi230050r23","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1001\/jama.2020.6504","article-title":"Accuracy of the PHQ-2 alone and in combination with the PHQ-9 for screening to detect major depression: systematic review and meta-analysis.","volume":"323","author":"Levis","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"ooi230050r24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jpainsymman.2011.03.019","article-title":"Prevalence of secondary lymphedema in patients with head and neck cancer.","volume":"43","author":"Deng","year":"2012","journal-title":"J Pain Symptom Manage"},{"issue":"9","key":"ooi230050r25","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1159\/000511482","article-title":"Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index.","volume":"111","author":"Shaunfield","year":"2021","journal-title":"Neuroendocrinology"},{"issue":"5","key":"ooi230050r26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s11136-018-1829-0","article-title":"COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study.","volume":"27","author":"Terwee","year":"2018","journal-title":"Qual Life Res"},{"key":"ooi230050r15","volume-title":"The Discovery of Grounded Theory","author":"Glaser","year":"1967"},{"key":"ooi230050r11","unstructured":"US Food & Drug Administration. Patient-Focused Drug Development: Collecting Comprehensive and Representative Input. 2020. Accessed July 17, 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input"},{"key":"ooi230050r12","unstructured":"US Food & Drug Administration. Patient-Focused Drug Development: Methods to Identify What Is Important to Patients. 2022. Accessed July 17, 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2808658\/jamaotolaryngology_gharzai_2023_oi_230050_1696269110.19483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T15:02:06Z","timestamp":1697122926000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2808658"}},"subtitle":["The FACT-HN-RAD Patient-Reported Outcome Measure"],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2023.2177","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}